← Eichor
Condition: Platinum Resistant Recurrent Ovarian Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Platinum Resistant Recurrent Ovarian Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06305299Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Phase 2 · 2 location(s) · Ira Winer · NCT04055649Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Phase 1 · 2 location(s) · Dana-Farber Cancer Institute · NCT06321484A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Phase 2 · 17 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT06434610Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05753826First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent
Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06994195A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Phase 2 · 1 location(s) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · NCT06522828Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Phase 1 · 4 location(s) · Outpace Bio, Inc. · NCT07030907DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Phase 1 · 3 location(s) · Elizabeth Stover, MD, PhD · NCT06964009Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Phase 3 · 1 location(s) · Chipscreen Biosciences, Ltd. · NCT04921527MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Phase 1 · 1 location(s) · Mayo Clinic · NCT06483048Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Pro
NA · 1 location(s) · The First Hospital of Jilin University · NCT07495384Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Phase 2 · 1 location(s) · Loyola University · NCT05983276SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT06394492HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3 · 1 location(s) · Hansoh BioMedical R&D Company · NCT06855069A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 14 location(s) · Context Therapeutics Inc. · NCT06515613Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Xing Xie · NCT04518501Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
Phase 1 · 1 location(s) · Stanford University · NCT06646627Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07540403IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment
Phase 2 · 1 location(s) · InxMed (Shanghai) Co., Ltd. · NCT06014528A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Com
Phase 2 · 2 location(s) · ImmunityBio, Inc. · NCT06710288Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Tr
EARLY_Phase 1 · 1 location(s) · Second Xiangya Hospital of Central South University · NCT06660511Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo
Phase 1 · 14 location(s) · National Cancer Institute (NCI) · NCT05950464
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.